Optimum chemotherapy in the management of metastatic pancreatic cancer

Table 4 Recent phase II trials studying new agents in the metastatic pancreatic cancer

Reference	New agents	Agents target	Phase of the study and targeted population	Arms of the study	Conclusion of the study
Kindler et al[26]	Ganitumab (AMG479)	mAb antagonist of insulin-like growth factor 1 receptor	Phase II; untreated MPC patients	Gem/ganitumab vs gem	Improved 6-mo survival rate and OS
Bodoky et al[27]	Selumetinib (AZD6244)	Selective MEK inhibitor	Phase II; second line treatment after gemcitabine	Selutimumab vs capecitabine	No significant difference in OS
Wolpin et al[28]	Everolimus (RAD001)	m-TOR inhibitor	Phase II; second line treatment after gemcitabine	Everolimus (single arm study)	Minimal clinical activity
Royal et al[31]	Ipilimumab (MDX010)	Anti-CTLA4	Phase II; untreated MPC patients	Ipilimumab (single arm study)	Ineffective in the treatment of MPC
Wolpin et al[36]	AGS-1C4D4	mAb to prostate stem cell Antigen	Phase II; untreated MPC patients	Gemcitabine/AGS-1C4D4 vs gemcitabine	Improved 6-mo survival rate

MPC: Metastatic pancreatic cancer; OS: Overall survival.